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Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by
erythema, pruritus, and scaling of skin. AD is clinically diagnosed by these essential
features, and the diagnosis is supported by early age of onset, personal or family history
of atopy, and xerosis.1 AD has a complex, heterogeneous etiology that includes barrier
defects, intrinsic immunological hyperactivity, and extrinsic triggers.2,3 According to a
recent study of lifetime worldwide AD prevalence over the period of 1990–2010, there
is no overall global trend in the prevalence of AD.4 However, a steady increase in AD
prevalence in developing countries has been observed. In general, AD is estimated
to affect up to 20% of children in developed countries and 3% of adults worldwide,
with up to 50% of pediatric AD cases persisting into adulthood.5,6 In the USA, 10.7%
of children and 3.2% of adults are living with AD.7,8
For patients with moderate-to-severe AD, skin lesions encompassing large surface areas are often associated with severe itching. These lesions can cause sleep
disturbances and, in turn, symptoms of anxiety, depression, and poor quality of life.9
Topical steroids, topical immunomodulators, and phototherapy are often inadequate
in providing sustained improvement in these patients, despite the additive benefit of
topicals in decreasing inflammation and restoring epidermal barrier function.2 For
patients with poor response to these topicals, the mainstay of treatment is systemic
immunosuppression, including oral corticosteroids, cyclosporine, or mycophenolate
41
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Abstract: Atopic dermatitis (AD) is a common inflammatory skin disorder that manifests as
eczematous lesions, often associated with allergic rhinitis and asthma. Historically, moderateto-severe disease has been managed with systemic immunosuppression, such as oral corticosteroids, which result in relapse and limiting side effects. Due to recent advancements in the
identification of interleukin (IL)-4 and IL-13 as key mediators in AD, new biological agents
have been developed for treatment. Dupilumab is a recently approved monoclonal antibody
that targets the alpha subunit of the IL-4 receptor and, thus, downregulates activity of IL-4 and
IL-13. This review discusses the profile of dupilumab and its potential for efficacy and safety
in treating moderate-to-severe AD by reviewing data from Phase I–III clinical trials. Results
suggest that dupilumab shows great therapeutic promise for AD. Further studies investigating
extended use of dupilumab and dupilumab in comparison to other agents are needed to establish
long-term efficacy and safety.
Keywords: atopic dermatitis, dupilumab, IL-4, IL-13, biologics
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mofetil. Though these medications may provide moderate
relief in AD, the risks often outweigh the benefits of longterm use. In particular, these oral agents are associated with
significant side effects such as increased infections, nausea/
vomiting, hypertension, and headaches.10,11 In a 10-year chart
review of the use of oral immunosuppressive drugs in patients
with severe AD, frequent reasons for discontinuation of
these therapies included ineffectiveness and adverse events,
such as neurological symptoms, gastrointestinal upset, and
fatigue/flu-like symptoms.11 Furthermore, for patients with
renal impairment and uncontrolled hypertension, oral corticosteroids, mycophenolate mofetil, and cyclosporine are less
viable treatment options due to their high risk to exacerbate
the underlying comorbidities.
Given the poor therapeutic responses, inconveniences,
and therapy-limiting side effects of conventional systemic
AD therapeutics, there is a substantial unmet need for more
efficacious and promising agents for moderate-to-severe AD
with minimal adverse effects. With recent advances in the
understanding of the pathological mechanisms of AD, new
biological agents have been developed and are being evaluated in clinical trials. In March 2017, dupilumab became
the first biologic to be approved by the US Food and Drug
Administration for inadequately controlled moderate-tosevere AD.12 The drug received this approval because of its
significant demonstration of efficacy and safety in treating
AD in three randomized Phase III pivotal trials. The purpose of this article is to review the findings on dupilumab
in clinical trials and examine the potential of the drug for
inadequately controlled moderate-to-severe AD.

Methods
Relevant articles on disease activity in AD and clinical trials
of dupilumab were searched and selected from the databases
of PubMed and ClinicalTrials.gov using the following terms:
dupilumab, AD, disease activity, interleukin (IL)-4, IL-13,
thymus and activation-regulated chemokine (TARC), eotaxin
3 (CCL26), comorbidity, quality of life, efficacy, biologic,
and adverse effects. Additional publications were collected
from references identified in articles and related citations in
PubMed. As of June 2017, Phase I, II, and III clinical trials of
dupilumab have been published. In total, 31 relevant papers
were reviewed and referenced.

Results
Pathogenesis and disease activity in AD
Ongoing debates regarding the pathogenesis of AD have
led to the following description of two forms of the disease:
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1) the intrinsic form resulting from abnormal epidermal
structure and function, and 2) the extrinsic form due to
cutaneous inflammation caused by immune responses to
extrinsic antigens.13,14 Moreover, there has been identification of increased activity of T lymphocytes secreting effector
cytokines and dysregulation of both cell-mediated immune
responses and inflammatory cascades in AD skin.13 Yet, over
the past several years, attention has been turned specifically
toward type 2 inflammatory mediators as targets for AD
therapy.
In particular, IL-4 and IL-13, cytokines from T helper type
2 (Th2) cells, are key mediators of the inflammation in AD.
These cytokines upregulate the expression of chemokines
such as TARC and CCL26.10,15–18 This increased expression
of TARC and CCL26 relates to increased disease activity,
including the selective migration of Th2 lymphocytes and
eosinophils into AD lesions, which cause inflammation.15–18
Additionally, in synergy with Toll-like receptor 2 ligands,
IL-4 potentiates the chronicity of AD through IL-4-mediated
suppression of IL-10.19 IL-4 and IL-13 also decrease the
keratinocyte expression of barrier proteins, such as filaggrin,
involucrin, and loricrin, triggering epidermal hyperplasia.20,21
Additional effects of these cytokines on keratinocytes
include the suppression of keratinocyte differentiation and
the synthesis of antimicrobial peptides and lipids.13,22,23 This
activity further disrupts the skin barrier through aberrant
expression of human β-defensins (hBD-2 and hBD-3) and
cathelicidin (LL-37) leading to an increase in the susceptibility of lesional skin to infection by microorganisms, such
as Staphylococcus aureus.13,24,25 Moreover, IL-4 and IL-13
induce B-cell differentiation leading to immunoglobulin E
(IgE) class switching.26 This phenomenon explains the elevation of IgE levels in AD, which is often associated with the
extrinsic form of the disease.10,27,28 Given that both IL-4 and
IL-13 act through a common receptor (IL-4 receptor alpha;
IL-4Rα), IL-4Rα has become a target of interest in treating
AD. Inhibition of IL-4Rα has resulted in normalization of
skin gene expression from lesional toward nonlesional skin,
reduction of TARC expression, and efficacy in the suppression of itch.10,28–30

Dupilumab: mechanism of action
Dupilumab is a fully human monoclonal antibody that binds
to the IL-4Rα, resulting in inhibition of both IL-4 and IL-13
signaling.10,12 This blockade by dupilumab reduces the type 2
helper T-cell-mediated inflammation cascade in AD. Specifically, competitive inhibition at the IL-4Rα inhibits activation of the signal transducer and activator of transcription
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6 (STAT6)/Janus kinase 1 (JAK1) signaling cascade (Figure 1).31,32 Overexpression of STAT6 has been demonstrated
to decrease epidermal differentiation complex genes, such as
the genes for loricrin and involucrin, and enhance penetration
of pathogens across the skin barrier leading to AD-like skin
disease in mice models.20,33

M4A and M4B trials were designed to assess safety as the
primary end point. From composite analysis of both studies,
by day 29, 59% of patients receiving dupilumab showed 50%
reduction in the Eczema Area and Severity Index (EASI)
score (EASI-50) compared to 19% of the placebo group
(Table 1). In addition, significant improvements in Investigator Global Assessment (IGA) scores and pruritus scores for
all dupilumab doses combined were observed in both studies.
Concerning safety data, nasopharyngitis and headache were
the most common side effects with no evidence of serious
adverse events in either trial.28,34
In addition to clinical improvement and safety, gene
expression profiles of lesional sites after 150 and 300 mg
dupilumab shifted to a more nonlesional molecular phenotype
within 4 weeks.34,35 Lesional skin showed overall improvement in transcriptome by 24% in the 150 mg dose group and
49% in 300 mg dose group compared to 21% in the placebo
group.28,34 Notably, markers of epidermal proliferation

Dupilumab: Phase I trials
In two 4-week randomized, double-blind, placebo-controlled,
dose-increasing Phase I trials, dupilumab was evaluated as
a monotherapy for moderate-to-severe AD in adults.28,34 In
the M4A trial, 30 subjects received 75, 150, or 300 mg of
subcutaneous dupilumab or placebo weekly for 4 weeks. The
subjects were randomly assigned to receive placebo or dupilumab in a 1:4 ratio. In the M4B trial, 37 subjects were studied
with 150 or 300 mg of subcutaneous dupilumab or placebo
weekly for 4 weeks. These subjects were also randomized
to receive placebo or dupilumab, but in a 1:3 ratio. Both the
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Figure 1 Receptor signaling for IL-4 and IL-13.
Notes: In hematopoietic cells, binding of IL-4 to type I IL-4Rα induces heterodimerization with γC, which activates JAK kinases and leads to the phosphorylation of
STAT6. Similarly, in nonhematopoietic cells, such as keratinocytes, hair follicles, and epithelial/smooth muscle cells, STAT6 is phosphorylated by the induction of the
heterodimerization of type II IL-4Rα and IL-13Rα1 after binding of the IL-4 or IL-13 to their respective receptors. Of note, IL-13 may bind to IL-13Rα2; however, this
receptor lacks a signaling motif. Dupilumab binds the IL-4R subunit of both type I and type II IL-4 receptors leading to inhibition of the JAK/STAT signaling cascade.
Source: Copyright 2014. Dove Medical Press. Reproduced from Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: a novel treatment for asthma. J Asthma
Allergy. 2014;7:123–130.32
Abbreviations: IL, interleukin; IL-4Rα, IL-4 receptor alpha subunit; IL-13α1, IL-13 receptor alpha 1 subunit; IL-13α2, IL-13 receptor alpha 2 subunit; JAK, Janus kinase;
STAT, signal transducer and activator of transcription.
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Notes: aSubjects were adults older than 18 years with moderate-to-severe AD as defined by an IGA score of ≥3, a baseline EASI score of ≥12, and duration of disease of ≥3 years. Dupilumab refers to subjects receiving all doses. bSubjects
were adults older than 18 years with moderate-to-severe AD as defined by an IGA score of ≥3, a baseline EASI score of ≥16, and duration of disease of ≥3 years. Dupilumab refers to subjects receiving all doses. cSubjects were adults
older than 18 years with moderate-to-severe AD as defined by duration ≥3 years, screening EASI ≥12, baseline EASI ≥16, baseline IGA ≥3. Dupilumab refers to patients receiving the 300 mg dose every other week. All mean percent
changes were calculated as percent change in least squares mean.
Abbreviations: AD, atopic dermatitis; EASI, Eczema Area and Severity Index; EASI-50, proportion of patients at 50% reduction in EASI; EASI-75, proportion of patients at 75% reduction in EASI; GCS, glucocorticoids; IGA, Investigator’s
Global Assessment; N/A, not assessed; SCORAD, Scoring Atopic Dermatitis; SE, standard error.
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(K16 and K6B, which reduced epidermal hyperplasia) were
downregulated by dupilumab.34,35 T-cell markers and other
inflammatory mediators, such as chemokines, were also
downregulated by dupilumab. Dupilumab also upregulated
genes related with skin barrier functions such as structurerelated gene, MATN4, lipid-metabolism-related genes,
PLIN4, ADIPOQ, and PLIN1, and barrier-related function
genes, CLDN8, ELN, and CLDN11.35

Dupilumab: Phase IIa trials
In a 12-week-long monotherapy study, M12, dupilumab
demonstrated significant improvement in reduction of
involvement and severity of AD in adults with moderate-tosevere disease. In the M12 study, subjects were randomized
to receive subcutaneous 300 mg dupilumab (n=55) or placebo
(n=54) weekly for 12 weeks. Dupilumab resulted in substantial improvement in multiple clinical measures in EASI-50,
EASI-75, and IGA scores (Table 1), and pruritus numerical
rating scale (NRS) score by day 85. Of note, 85% of patients
on dupilumab achieved EASI 50 compared to 35% in the
placebo group. Overall, pruritus NRS scores decreased by
56% in the dupilumab group compared to 15% in the placebo
group. Serum TARC and serum IgE levels also decreased
significantly more in dupilumab patients.28,34
In a 4-week-long randomized, double-blind, parallelgroup, placebo-controlled clinical trial (C4), dupilumab was
also evaluated in combination with topical corticosteroids
(TCSs). Subjects were randomized in a 2:1 ratio to receive
subcutaneous 300 mg dupilumab (n=21) or placebo (n=10)
weekly for 4 weeks in combination with a regimen of TCSs.
The primary end points were the occurrence and severity
of adverse events. All subjects in the dupilumab plus TCS
group achieved EASI-50 by 4 weeks, while only 50% in
the placebo plus TCS group achieved the same (Table 1).28
Again, the dupilumab group showed significant improvement
in pruritus NRS and IGA scores compared to the placebo
group. Moreover, the dupilumab group used 50% less TCSs
in comparison to the placebo group. There was also a greater
decline of TARC and IgE levels in the dupilumab group.28,34 In
the combined safety data for studies of M4A, M4B, M12, and
C4, adverse events occurred at similar rates in the dupilumab
and placebo groups.34

Dupilumab: Phase IIb trial
In an international, multicenter, randomized, double-blind,
dose-ranging, placebo-controlled clinical trial, the efficacy
and safety of five different dosings of dupilumab were
evaluated over a period of 16 weeks. Subjects were r andomly
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Notes: aSubjects were adults older than 18 years with moderate-to-severe AD as defined by an IGA score of ≥3, a baseline EASI score of ≥16, baseline BSA of ≥10%, and duration of disease of ≥3 years. Dupilumab refers to the 300 mg
dose. bSubjects were adults older than 18 years with moderate-to-severe AD as defined by duration ≥3 years, screening EASI ≥12, baseline EASI ≥16, baseline IGA ≥3. Dupilumab refers to 300 mg dose.
Abbreviations: AD, atopic dermatitis; EASI, Eczema Area and Severity Index; EASI-50, 50% reduction in EASI; EASI-75, 75% reduction in EASI; EASI-90, 90% reduction in EASI; EOW, every other week; GCS, glucocorticoids; IGA,
Investigator’s Global Assessment; LS mean, least squares mean; SCORAD, Scoring Atopic Dermatitis; SE, standard error.
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Dupilumab: Phase III trials
In 2016, two identically designed Phase III trials of dupilumab
were carried out for subjects with moderate-to-severe AD.
Subjects were randomly assigned in a 1:1:1 ratio to receive,
subcutaneous 300 mg dupilumab or placebo weekly or the
same dose of dupilumab every other week alternating with
placebo for 16 weeks. The primary outcome was the proportion of subjects who had both a score of 0 or 1 (clear or almost
clear) on IGA and a reduction of 2 points or more in that score
from baseline at week 16. Over 600 patients participated in
each trial, with 671 subjects for SOLO 1 and 708 subjects
for SOLO 2 randomized to receive dupilumab or placebo. In
SOLO 1, the primary outcome point was achieved by 38%
of patients receiving dupilumab every other week, 37% of
those receiving dupilumab weekly, and 10% of subjects who
received placebo (Table 2). SOLO 2 demonstrated comparable
results, with 36% of patients in both dupilumab groups and
8% of the placebo group reaching the primary outcome point.
Additionally, those in the placebo group received more rescue
treatment than those in the dupilumab groups.30
In both trials, dupilumab significantly decreased patientreported symptoms of AD, with improvement in sleep,
anxiety, depression, and, therefore, quality of life of subjects.
In Dermatology Life Quality Index (DLQI) and PatientOriented Eczema Measure (POEM) scores, dupilumab
groups demonstrated twice as much improvement compared
to placebo groups. At week 16, among the subjects who had
Hospital Anxiety and Depression Scale (HADS)-Anxiety or
HADS-Depression scores ≥8 at baseline, significantly more
dupilumab-treated subjects had HADS scores of <8 compared
to the placebo group.30
In a 1-year-long randomized, double-blinded, placebocontrolled clinical trial (LIBERTY AD CHRONOS),

Phase III 52 weeksb

LIBERTY AD CHRONOS12

Dupilumab
+ topical
GCS weekly
(N=270)

assigned to receive subcutaneous placebo (n=61) or dupilumab 100 mg (n=65) monthly, 300 mg (n=65) monthly, 200
mg (n=61) every 2 weeks, 300 mg (n=64) biweekly, and
300 mg (n=63) weekly. By week 16, dupilumab showed
improved EASI scores and resulted in significant improvement in SCORAD (Scoring Atopic Dermatitis) scores in a
dose-dependent manner (Table 1). All of the 300 mg dupilumab dose regimens resulted in more than 3 points decrease
in pruritus NRS scores in 37%–54% of subjects versus 8%
of subjects in the placebo group. Furthermore, dupilumab
resulted in early and sustained improvement in depression,
anxiety, and quality-of-life scores. Mean percentage changes
in TARC at week 16 correlated with clinical outcomes such
as EASI, SCORAD, and IGA scores.29
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Table 2 Clinical efficacy and safety in Phase III trials
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d upilumab was evaluated as concomitant therapy with
TCSs in adults with moderate-to-severe AD and inadequate
response to TCSs alone.12 Subjects were randomized in a
3:1:3 ratio to receive subcutaneous 300 mg dupilumab weekly
(n=319), 300 mg dupilumab every 2 weeks (n=106), or placebo (n=315), with all three groups receiving concomitant
TCSs with or without topical calcineurin inhibitors (TCI)
tapered, discontinued, or restarted on the basis of disease
activity. By week 16, 39% of patients in each dupilumab
group achieved the coprimary endpoint of IGA 0/1 compared
to 12% in the placebo group (Table 2). The other coprimary
endpoint of 75% reduction in EASI score (EASI-75) was
achieved by 64% of the weekly dupilumab group, 69% of the
dupilumab every other week group, and 23% of the placebo
group. Overall, patients receiving dupilumab had more days
free of TCSs/TCI and/or systemic rescue medication use
than those in the placebo group at 16 weeks and 52 weeks.

Additionally, corresponding SCORAD, POEM, HADS, and
DLQI scores were significantly reduced in the dupilumab
groups compared to the placebo group.12 Improvement of
NRS and DLQI scores in all three Phase III trials for dupilumab patients is demonstrated in Figures 2 and 3.12,30

Discussion
Literature concerning the impact of dupilumab in the pathogenesis of AD includes Phase I, II, and III clinical trials.
Results from these trials show that dupilumab improves clinical symptoms of moderate-to-severe AD and decreases T-cell
markers, markers of epidermal proliferation, and inflammatory
mediators and chemokines.28 In particular, compared to placebo and lower doses, the 300 mg dose of dupilumab demonstrated the greatest improvement in EASI and NRS scores,
and transcriptome of lesional skin in Phase I and II studies.28,34
Moreover, the 300 mg dose every other week resulted in similar

Dupilumab every other week
Dupilumab weekly

Week 16 SOLO 2

Placebo
Dupilumab + TCS every other week

Week 16 SOLO 1

Dupilumab + TCS weekly
Placebo + TCS

Week 52 phase III LIBERTY AD
CHRONOS trial
Week 16 phase III LIBERTY AD
CHRONOS trial
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40
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Figure 2 Percentage of patients who achieved peak pruritus numerical rating scale score improvement ≥4 points from baseline in Phase III trials.
Abbreviations: AD, atopic dermatitis; TCS, topical corticosteroid.
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Figure 3 Least squares mean change in Dermatology Life Quality Index score from baseline in Phase III trials.
Abbreviations: AD, atopic dermatitis; TCS, topical corticosteroid.
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efficacy to the 300 mg weekly dose in achieving primary and
secondary outcome measures in Phase III trials.12,30 Notably,
the greatest percentage of patients achieved improvement in
EASI or IGA when dupilumab was administered at 300 mg
every other week with concomitant TCS use.12
Additionally, the frequency of adverse events was demonstrated to be similar between placebo and dupilumab groups,
with the most commonly reported adverse events including
headaches and nasopharyngitis in Phase I and II trials.28
In comparison, the most common adverse events reported
in Phase III trials were exacerbations of AD (10%–18%),
injection-site reactions (15%–19%), and nasopharyngitis
(10%–23%), with conjunctivitis also occurring in 14% or
more of patients on dupilumab in the 1-year-long Phase III
trial.12,30 Of note, in Phase I and II trials dupilumab also demonstrated decreased total number of skin infections compared
to placebo (4%–5% versus 10%–24%).28 Moreover, across
the four Phase I and II trials, the rate of skin infections in
the placebo groups was 0.2 per patient compared to 0.05
infections per patient in the dupilumab groups.28 This particular finding supports the concept that dupilumab improves
epidermal barrier function.
In addition to its clinical efficacy, dupilumab also demonstrated improved quality of life as well, with significant
reduction of DLQI and POEM scores.30 Overall, these results
suggest that IL-4 and IL-13 are important mediators in the
pathogenesis and morbidity of AD. However, additional trials
over an extended period of time are necessary to establish a
long-term safety and efficacy profile of dupilumab.
The recent recognition of AD as a predominantly Th2mediated disease has led the way for the investigation of
a variety of therapeutics that target specific inflammatory
mediators involved in innate immunity. Multiple biologics
are currently being investigated in clinical trials, including
antibodies that specifically target IL-13, IL-17, IL-22, IL-31,
and IL-12/IL-23p40.36 Topical and oral phosphodiesterase-4
inhibitors are also being investigated in Phase II and Phase
III clinical trials, along with a JAK inhibitor and therapeutics
targeting thymic stromal lymphopoietin and chemoattractant
receptor-homologous molecule expressed on Th2 cells.36
These novel therapies have shown promising results. Notably,
IL-31 inhibition has shown significant reduction of pruritus
in patients with AD.37 Yet, despite these ongoing investigations into the use of multiple biologics for treatment of AD,
dupilumab remains the first and only biologic to be approved
for moderate-to-severe AD.
Prior to the development of dupilumab, treatments
available for AD included topical and oral glucocorticoids,
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calcineurin inhibitors, cyclosporine, methotrexate, azathioprine, and mycophenolic acid precursors. Currently, there
are no studies comparing dupilumab to other systemic treatments approved for AD. However, prior to the approval of
dupilumab, a systematic review of 34 randomized control
trials involving 1,653 patients compared the efficacy and
safety of 12 systemic treatments using the Grading of Recommendations Assessment, Development, and Evaluation
approach.38 Azathioprine and methotrexate were recommended as second- and third-line treatments, respectively,
according to moderate-quality evidence.38 Cyclosporine A
(CsA) received the strongest recommendation as a first-line
treatment for short-term use in AD. Additionally, evidence
based on four trials demonstrated that long-term treatment
with CsA can be recommended for up to 1 year.38–42 However,
comparison of associated risks of long-term use of CsA, such
as nephrotoxicity and hypertension, to that of year-long use of
dupilumab, such as nasopharyngitis and conjunctivitis, suggests that dupilumab is likely a safer long-term option.12,39–43
Yet, due to variations in trial designs, it is problematic to
compare safety and efficacy data between studies of systemic
treatments and dupilumab.29,38
Future evaluations should focus on comparing the efficacy and safety of dupilumab against available systemic
treatments in head-to-head trials. In addition, further studies
observing the long-term efficacy and safety of dupilumab are
also needed. In particular, extended observation to assess
immunogenicity is warranted. Specifically, an assessment of
the development of neutralizing antibodies over long-term
use may provide further insight into how immunogenicity
may affect long-term efficacy of dupilumab. Overall, the
administration of dupilumab every other week and its relative safety and efficacy offer a convenient and lower-risk
alternative to currently available systemic treatments for
moderate-to-severe AD.
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